Home › with Excess of Blasts Refractory Anemia › Massachusetts › Boston
with Excess of Blasts Refractory Anemia clinical trials in Boston, MA
3 studies for with Excess of Blasts Refractory Anemia are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
- Massachusetts General Hospital, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- Dana-Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
- Dana-Farber Cancer Institute, Boston
with Excess of Blasts Refractory Anemia trials in other cities
- Houston, TX6 studies
- Seattle, WA5 studies
- New York City, NY3 studies
- Washington, DC3 studies
- Columbus, OH3 studies
Other studies in Boston
- Breast Cancer112 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)85 studies
- Metastatic Cancer63 studies
- Colorectal Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.